Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: J Thorac Oncol. 2017 Nov 20;13(2):228–236. doi: 10.1016/j.jtho.2017.11.109

Table 3.

Survival data according to EGFR/CEP7 ratio (≥ 2 vs. < 2).

EGFR/CEP7 RATIO
≥ 2 < 2
ARM A ARM B ARM A ARM B
N 18 16 264 259
Median OS (95% CI) 12.11 (9.43, 31.51) 7.62 (4.99, 19.06) 11.73 (10.51, 13.60) 9.99 (8.90, 11.93)
HR within subgroup (interaction model) 0.63 (0.29, 1.37) p = 0.245 0.91 (0.75, 1.11) p = 0.355
Interaction p-value 0.365
Median PFS (95% CI) 7.36 (3.75, 11.40) 5.55 (2.76, 9.99) 5.72 (5.55, 6.47) 5.49 (4.60, 5.62)
HR within subgroup (interaction model) 0.80 (0.36, 1.78) p = 0.581 0.91 (0.75, 1.11) p = 0.345
Interaction p-value 0.752

Arm A: cisplatin-gemcitabine-necitumumab; Arm B: cisplatin-gemcitabine.

CEP7: chromosome 7; CI= confidence interval; EGFR: epidermal growth factor receptor (gene) HR= hazard ratio; OS: overall survival; PFS: progression-free survival.